Clinical use of calcium channel blockers as ventricular unloading agents

European Heart Journal
|January 1, 1983
PubMed

Insights

Nifedipine effectively treated hypertensive heart failure by reducing blood pressure and improving cardiac function, unlike verapamil which showed limited benefits and potential side effects.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Calcium channel blockers are used to manage hypertension and heart failure.
  • Hypertensive patients with cardiac enlargement present unique challenges for treatment.

Purpose of the Study:

  • To compare the efficacy of nifedipine and verapamil in hypertensive patients with cardiac enlargement and heart failure symptoms.
  • To evaluate the acute and chronic effects of these drugs on hemodynamic parameters and cardiac function.

Main Methods:

  • A comparative study involving 23 hypertensive patients with cardiac enlargement.
  • Patients received either nifedipine or verapamil in acute and 1-month therapeutic evaluations.
  • Hemodynamic parameters, including systemic vascular resistance (SVR), mean arterial pressure (MAP), pulmonary wedge pressure (PWP), left ventricular diastolic diameter (LV DD), cardiac index (CI), and Vcf, were measured.

Main Results:

  • Nifedipine significantly reduced SVR, MAP, PWP, and LV DD, while improving CI and Vcf, with relief of dyspnea and lung congestion.
  • Verapamil reduced SVR and MAP, improved CI, but did not significantly affect PWP, LV DD, or Vcf. Two patients discontinued verapamil due to severe dyspnea.
  • Nifedipine demonstrated superior efficacy in improving cardiac function and relieving heart failure symptoms compared to verapamil.

Conclusions:

  • Nifedipine is a more effective ventricular unloading agent than verapamil in hypertensive patients with cardiac enlargement and heart failure.
  • The differing effects may be due to verapamil's less potent vasodilation and greater depression of cardiac contractility.
  • Nifedipine offers a favorable therapeutic option for managing functional changes in the failing hypertensive heart.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
2.4K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
2.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.7K